Menu

Djamel NEHAR-BELAID, PH.D.

PARIS

Electionseuropéennes 2024

RETROUVEZ GRATUITEMENTLe résultat des européennes à Paris.

En résumé

I am interessted in data analysis and have a passion for problem-solving. I thrive searching for creative solutions for interpretation and visualization of OMICs data. I am dedicated to contribute in the search for solutions to unmet medical needs.

Mes compétences :
Biotechnologies
Gestion de projet
Systems Immunology

Entreprises

  • I3 lab (Immunology - Immunopathology - Immunotherapy) - Postdoctoral Researcher

    2014 - maintenant Project : Systems immunology to the study of the tumour microenvironment and the maternal-fetal interface.

  • I3 lab (Immunology - Immunopathology - Immunotherapy) - Ph.D. Student

    2011 - 2014 Project :
    A systems immunology approach to the study of uterine and tumor microenvironments

    There are striking similarities between fetus and tumor development. They both require intense cell division, invasion of host tissues and sustained vascularization. Moreover, despite that fetus and tumor express foreign antigens - paternal allo-antigens for fetuses and modified auto-antigens for tumors - they are not rejected by the immune system.
    Among others, regulatory T cells (Tregs), which are key players in tolerance, appear to play a significant role in both processes
    We showed that tumor emergence as well as embryo implantation elicit a strikingly similar brisk Treg response, which functional relevance is supported by the fact that and Treg depletion leads to fetus or tumor immune rejection.
    Comparison of fetal and tumor microenvironments through transcriptomics revealed strikingly similar and dramatic decrease in expression of multiple immune-related pathways, including antigen presentation and T cell response. Unsupervised analyses highlighted the co-evolution in time of down-regulated immune signatures, from the very first days after tumor or embryo implantation. Treg depletion, which leads to fetus or tumor rejection, converted the very same down-modulated immune signatures to up-regulated ones. We propose that means selected during evolution to protect mammalian fetuses are hijacked to license tumor development.


    Team leader : Pr.David KLATZMANN

Formations

  • Université Paris 6 Pierre Et Marie Curie

    Paris 2011 - 2014 PH.D

    Gestion de projet, génération données transcriptomiques, Analyse de jeux de données OMICs, Analyse supervisée et non supervisée, programmation sous R, visualization (cytoscape), Annotation fonctionnelle de gènes (Ingenuity Pathway Analysis), Gene set enrichment analysis (GSEA).

  • Université Paris 6 Pierre Et Marie Curie

    Paris 2009 - 2010 Gestion de projet, communication orale et écrite, team working

Réseau

Annuaire des membres :